Previous 10 | Next 10 |
Molecular Templates (NASDAQ: MTEM ) files for 9,440,392 share offering by selling shareholders. More news on: Molecular Templates, Inc., , Healthcare stocks news, Read more ...
Molecular Templates (NASDAQ: MTEM ) has secured a debt financing facility for up to $45M from K2 HealthVentures, a healthcare-focused specialty finance company. More news on: Molecular Templates, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’...
AUSTIN, Texas,, May 15, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biol...
AUSTIN, Texas, May 13, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bod...
Many investors tend to stay away from stocks that are appreciating strongly over time, mostly because of fears of buying too late when the stock is already overvalued. Having some patience when looking for entry prices and being conscious about valuation is very important. However, blindly avo...
Molecular Templates (NASDAQ: MTEM ): Q1 GAAP EPS of -$0.48 misses by $0.21 . More news on: Molecular Templates, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
AUSTIN, Texas, May 11, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biolo...
AUSTIN, Texas, May 07, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (the “Company”) (Nasdaq: MTEM) announced today that the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be held virtually due to the public health impact of the novel corona...
Menlo Therapeutics (NASDAQ: MNLO ) initiated with Overweight rating and $8 (161% upside) price target at Barclays. More news on: Menlo Therapeutics Inc., Molecular Templates, Inc., Passage Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Molecular Templates Inc. Company Name:
MTEM Stock Symbol:
NASDAQ Market:
Molecular Templates Inc. Website:
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineere...